---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-036113"
form_type: "8-K"
ticker: "ARWR"
cik: "0000879407"
company_name: "ARROWHEAD PHARMACEUTICALS, INC."
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T11:29:20.480050+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Arrowhead Q3 net loss $170.8M ($1.38/sh); secures $500M credit facility; plozasiran Phase 3 meets endpoints

## Summary
- Net loss of $170.8M ($1.38 diluted EPS) vs $102.9M ($0.96) a year ago; revenue nil vs $15.8M.
- Secured $500M non-dilutive credit facility from Sixth Street ($400M funded, $100M available) plus $50M milestone from Royalty Pharma.
- Pivotal Phase 3 PALISADE study of plozasiran in FCS met primary endpoint: triglycerides reduced up to 80%, APOC3 up to 94%, acute pancreatitis incidence reduced vs placebo.
- Initiated Phase 3 SHASTA-3/4 for plozasiran in severe hypertriglyceridemia; plans for Phase 3 CAPITAN cardiovascular outcomes trial.
- Cash and investments $436.7M at June 30, 2024, up from $403.6M at Sept 30, 2023; company approaching plozasiran launch in 2025 if approved.

## SEC filing metadata
- accession: 0001628280-24-036113
- form_type: 8-K
- ticker: ARWR
- cik: 0000879407
- company_name: ARROWHEAD PHARMACEUTICALS, INC.
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/879407/000162828024036113/0001628280-24-036113-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/879407/000162828024036113/arwr-20240808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-036113
- JSON: https://secwatch.observer/filing/0001628280-24-036113.json
- Plain text: https://secwatch.observer/filing/0001628280-24-036113.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.